Fermenta Biotech Limited will hold a one-to-one meeting with investors on July 23, 2026, in Mumbai. The interaction is being conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company stated that relevant press releases and investor presentations proposed for discussion are available on its website and the BSE Limited website. Fermenta Biotech clarified that no unpublished price sensitive information (UPSI) is intended to be shared during the meeting.

Changes to the schedule may occur due to exigencies on the part of the company or the investors.

Fermenta Biotech Limited has secured approval from the Food Safety and Standards Authority of India (FSSAI) for its plant-based Vitamin D3 product, VITADEE Green®. This regulatory clearance enables the company to market its Vitamin D3 (Cholecalciferol) – Plant Source, a product developed and manufactured entirely within India. The approved product is permitted for use in health supplements, nutraceuticals, and food items, broadening its application across India's nutrition landscape. The approval supports the Make in India initiative and enhances the nation's self-reliance in nutrition solutions.

Regulatory Filing Details

The company informed BSE Limited regarding this development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was officially submitted on July 3, 2026.

Product and Strategic Impact

The newly approved VITADEE Green® represents a significant addition to Fermenta Biotech's portfolio. The following table summarises the key details of the approved product and its regulatory context:

By manufacturing this plant-based Vitamin D3 domestically and enabling its use across multiple nutrition categories, Fermenta Biotech aims to contribute to the government's vision of local production and reduced dependency on imports for critical nutritional ingredients.